Kyoto Prize winner Shinya Yamanaka, who invented a way to derive stem cells from skin cells, is working with ViaCyte to bring to market a treatment for diabetes.

Kyoto Prize winner Shinya Yamanaka, who invented a way to derive stem cells from skin cells, is working with ViaCyte to bring to market a treatment for diabetes. Photo by Photo courtesy of Chris Goodfellow/Gladstone Institutes

VIACYTE

CEO: John S. West.

Financial information: Not disclosed.

No. of local employees: 40.

Investors: Privately held, venture capital backed.

Headquarters: Torrey Pines, branch in Athens, Ga.

Year founded: Founded in 1999 as Novocell Inc., the company merged with CyThera and Bresagen in 2004, and changed its name to ViaCyte in 2010.

Company description: ViaCyte is a preclinical therapeutic company focused on diabetes, developing therapies with human embryonic stem cell lines.

A San Diego company that is working to bring to market a treatment for diabetes derived from embryonic stem cells is also working with Kyoto Prize winner Shinya Yamanaka — whose invention of a way to derive stem cells from skin cells has been called “the most important stem cell breakthrough of all time...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $99